U.S. markets open in 6 hours 25 minutes

Sotera Health Company (SHC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.84-0.02 (-0.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close25.86
Bid0.00 x 1000
Ask0.00 x 900
Day's Range25.58 - 26.07
52 Week Range23.84 - 30.38
Avg. Volume1,374,447
Market Cap7.31B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Sotera Health Company (SHC) Q4 2020 Earnings Call Transcript
      Motley Fool

      Sotera Health Company (SHC) Q4 2020 Earnings Call Transcript

      The company would like me to read the following forward-looking statement on their behalf. Michael Petras, chairman and chief executive officer; and Scott Leffler, chief financial officer, will be making comments on today's call, followed by a question-and-answer period.

    • Sotera Health’s 4Q Results Beat Analysts’ Expectations As Sales Outperform; Street Says Buy

      Sotera Health’s 4Q Results Beat Analysts’ Expectations As Sales Outperform; Street Says Buy

      Sotera Health reported better-than-expected 4Q results driven by top-line growth in all segments. Shares of the integrated health and sterilization services provider plunged 4.4% to close at $25.50 on March 8. Sotera Health’s (SHC) 4Q adjusted earnings more than doubled to $0.09 per share on a year-over-year basis and beat the Street estimates of $0.07 per share. Revenues advanced 12% to $217 million and surpassed the consensus estimate of $212.29 million. The company’s adjusted EBITDA came in at $113 million, up 20% year-over-year. (See Sotera Health stock analysis on TipRanks) Sotera Health CEO Michael B. Petras, Jr. commented, “Our three businesses – Sterigenics, Nordion and Nelson Labs – successfully navigated a global pandemic, pivoting to meet increased demand for products and services critical to protecting against the coronavirus, while ensuring continuity and quality of service for our broad-spectrum of healthcare customers.” For 2021, the company projects adjusted EPS to range from $0.78 to $0.86 per share, versus the consensus estimate of $0.69. Net revenues are anticipated to be in the range of $890 million to $920 million, versus analysts’ expectations of $894.7 million. Adjusted EBITDA is expected to land between $465 million to $485 million. On March 2, Barclays analyst Luke Sergott initiated coverage of the stock with a Buy rating and a price target of $35 (37.3% upside potential). The analyst highlights “the company’s position as one of only a few global providers of sterilization and lab testing services, which is a tightly regulated space with high barriers to entry and a sticky customer base.” “A closer look at the gamma radiation sterilization business reveals plenty to appeal to a cash flow investor, including a high-single-digit growth rate driven by stable and rising demand for mission-critical sterilization services,” Sergott added. The consensus rating among analysts is a Strong Buy based on 9 unanimous Buys. The average analyst price target stands at $32.61 and implies upside potential of almost 28% to current levels over the next 12 months. Additionally, Sotera Health scores an 8 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Hibbett 4Q Profit Exceeds Estimates As E-commerce Sales Boom; Shares Tank 4% Big Lots’ 4Q Profit Beats Analysts’ Estimates As Comparable Sales Rise; Shares Gain 2% Cooper’s 1Q Results Beat The Street Consensus; Street Says Buy More recent articles from Smarter Analyst: Thor Posts Better-Than-Expected Q2 Results Stitch Fix Plummets 22% In Pre-Market On Softer FY21 Revenue Outlook Waitr Disappoints With 4Q Results; Shares Slide 15% ContextLogic’s 1Q Revenue Outlook Exceeds Expectations After 4Q Beat; Shares Rise

    • 10 Best New Stocks To Buy Now
      Insider Monkey

      10 Best New Stocks To Buy Now

      In this article, we shared the 10 best new stocks to buy now. You can skip our discussion of the current situation of the financial markets and go directly to 5 Best New Stocks to Buy Now. Let’s face it: investing isn’t as easy as it seems, especially in the age of meme stocks, outrageous […]